Science & Leadership
Scientific leadership at GMPriority Pharma is focused on ensuring liposomal systems can be formulated, manufactured and supplied within controlled, regulated environments — not just designed in theory.
Science as Leadership
Applied science, not theoretical development
Our scientific capability supports structured development, rigorous characterisation and disciplined scale-up, ensuring liposomal systems maintain consistency from early formulation through to commercial production.
We focus on how delivery systems behave under real processing conditions, not just laboratory models.
Built on lipid-based delivery systems
GMPriority Pharma’s expertise is grounded in extensive applied work with lipid-based and liposomal systems across development and manufacturing contexts.
Core scientific capabilities include:
- Lipid and liposomal formulation design
- Structural and physicochemical characterisation
- Process development for controlled scale-up
- Manufacturing integration within GMP-aligned frameworks
Scientific activity is conducted within an integrated environment where development and production teams operate together — providing continuity between formulation and manufacture.
Led by Professor Mohammad Najlah
Scientific direction is led by Professor Mohammad Najlah,
Chief Scientist and Co-Founder.
Professor Najlah brings extensive experience in:
Δ Lipid-based delivery systems
Δ Translational formulation science
Δ Applied pharmaceutical and nutraceutical research
His work focuses on how delivery systems respond to formulation variables, processing conditions and scale-up.
_______________________________
Scientific leadership includes:
- Technical strategy and scientific governance
- Oversight of formulation and process development
- Alignment of academic collaboration with applied manufacturing outcomes
Under Professor Najlah’s direction, GMPriority Pharma continues to explore advanced delivery architectures and processing approaches:
Novel lipid structuring techniques
Controlled particle engineering strategies
Emerging formats such as non-conventional and inverted liposomal systems
Translation of research concepts into manufacturable processes
Elements of this work contribute to ongoing intellectual property development, proprietary methodologies and protected process know-how.
Academic & Industrial Collaboration
Connected to applied research
GMPriority Pharma maintains active engagement with academic and publicly funded research programmes where appropriate.
Collaborative work supports continued refinement of:
- Liposomal processing
- Structural characterisation
- Manufacturing methodologies
This allows that production capability remains informed by current scientific understanding — while grounded in manufacturable outcomes.
Research associated with our scientific leadership has contributed to broader work in areas such as:
Lipid-based drug delivery
Controlled release systems
Translational therapeutic applications, including oncology-focused research
From research to real-world systems
Many liposomal technologies fail during scale-up.
Our scientific approach is designed to ensure that what is developed:
can be processed
can be reproduced
can be manufactured at scale
